Tipping the GVH/GVL balance by targeting HIF1α

Yongxia Wu; Xue-Zhong Yu

doi:10.1016/j.xcrm.2023.101295

Tipping the GVH/GVL balance by targeting HIF1α

Cell Rep Med. 2023 Nov 21;4(11):101295. doi: 10.1016/j.xcrm.2023.101295.

Authors

Yongxia Wu¹, Xue-Zhong Yu²

Affiliations

¹ Department of Microbiology & Immunology, Medical College of Wisconsin, Milwaukee, WI, USA; Department of Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA.
² Department of Microbiology & Immunology, Medical College of Wisconsin, Milwaukee, WI, USA; Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA; Department of Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA. Electronic address: xuyu@mcw.edu.

Abstract

Promoting GVL activity while eliminating GVHD is the utmost goal to treat hematological malignancies with allo-HCT. Bailey et al. demonstrate that targeting HIF1α can favor GVL activity while limiting GVHD after allo-HCT even in combination with immune checkpoint inhibition.¹.

MeSH terms

Graft vs Host Disease*
Hematopoietic Stem Cell Transplantation*
Humans